Latest Commercial Rollouts News

Janus Electric has secured a A$10 million order from US fleet Ability Tri-Modal, lifting its North American diesel-to-electric truck conversions to 45 and advancing commercial rollouts in Canada and Australia.

Klevo Rewards has successfully completed a 14-day commercial trial of its stablecoin transaction platform, generating approximately USD 1.22 million in gross revenue and validating its payment capabilities.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

Zoono Group has reported a 94% jump in quarterly cash receipts to NZ$975K, turning cash flow positive amid expanding commercial rollouts of its shelf-life extension technology across multiple continents.

Swift TV has landed a second multi-site hospitality contract, expanding its footprint in premium Western Australian accommodation and reinforcing its recurring revenue model.

Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

Saluda Medical has obtained FDA approval for its CAP24 surgical paddle lead, a first-of-its-kind device designed for closed-loop spinal cord stimulation, poised to broaden its US market reach and engage new surgical specialties.

ikeGPS Group Limited reported a 33% surge in subscription revenue to NZ$19.2 million for FY26, driven by AI-powered product innovation and expanding adoption among North American utilities. The company achieved positive underlying EBITDA in March and ended the year with NZ$33 million cash and no debt.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

The a2 Milk Company has announced a $300 million fully franked special dividend following regulatory clearance in China to rebrand infant formula products under its a2 label.

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.